Adjuvant Immunotherapy with B.C.G. in Carcinoma of the Prostate

Robinson, M. R. G.; Rigby, C. C.; Pugh, R. C. B.; Dumonde, D. C.

doi:10.1111/j.1464-410x.1977.tb04108.x

Cited by 17 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is an obvious need for simpler, ideally noninvasive or minimally invasive, methods when prostate cancer is deemed to require curative treatment. The administration of biological modifiers in prostate cancer has enjoyed sporadic attention over the last four decades; animal models [1] and human clinical studies [2] have been reported to show anticancer activity. More recently, interest has rekindled in the administration of viral oncolytic and other immunotherapeutic agents for prostate cancer [3–6].…”

Section: Introductionmentioning

confidence: 99%

Intralesional recombinant α‐interferon for localized prostate cancer: a pilot study with follow‐up of >10 years

Emerson

Morales

2009

BJU International

View full text Add to dashboard Cite

OBJECTIVE To report the long‐term results of the intralesional administration of an immune modifier, interferon‐α (IFN‐α) in men with localized prostate cancer, providing a method for drug delivery within the gland under ultrasonographic control. PATIENTS AND METHODS Ten men with localized prostate cancer participated in a study involving the intraprostatic injection of IFN‐α, weekly for 5 weeks. Prostate biopsies were taken and prostate‐specific antigen (PSA) levels were measured bi‐annually or until the men had an alternative treatment. RESULTS The pretreatment mean Gleason score was 7 and the mean PSA level 11 ng/mL. Biopsies after treatment were negative in three patients. Of the remaining seven, six chose to continue watchful waiting. With time, five went on to alternative treatment; one had radical prostatectomy (at 3 months), two had external beam radiotherapy (at 3 and 6 months), and two had androgen suppression (at 3 and 24 months). Of the three men with initial negative biopsies, one died from unrelated causes 13 years later, with an undetectable PSA level; the second remains asymptomatic 13 years later but has an elevated PSA level. The last patient has a low (<4 ng/mL) PSA level, negative biopsies and had ‘no cancer’ in a resection specimen, 64 months after treatment. These two men remain under active surveillance with no intervention. CONCLUSIONS After delivery of IFN‐α directly into the prostate gland, and a long follow‐up, it appears that there was some antitumour activity in some patients. The doses used were small and the schedule of administration short. Further evaluation of this, and other agents alone and in combination, might be worthwhile.

show abstract

Section: Introductionmentioning

confidence: 99%

Intralesional recombinant α‐interferon for localized prostate cancer: a pilot study with follow‐up of >10 years

Emerson

Morales

2009

BJU International

View full text Add to dashboard Cite

show abstract

“…Between 1980 and 1999, some clinical trials that evaluated BCG post-operative treatment of renal cell carcinoma (RCC) were reported [129–132]. Furthermore, direct intratumor injection of BCG in patients with prostate cancer showed some benefits in early clinical trials as well [133;134]. Guinan et al .…”

Section: Bcg In Cancer Therapymentioning

confidence: 99%

Applications of bacillus Calmette–Guerin and recombinant bacillus Calmette–Guerin in vaccine development and tumor immunotherapy

Zheng

Naguib

Dong

et al. 2015

Expert Review of Vaccines

View full text Add to dashboard Cite

Summary Bacillus Calmette-Guerin (BCG) vaccines are attenuated live strains of Mycobacterium bovis and are among the most widely used vaccines in the world. BCG is proven effective in preventing severe infant meningitis and miliary tuberculosis. Intravesical instillation of BCG is also a standard treatment for non-muscle invasive bladder cancer. In the past few decades, recombinant BCG (rBCG) technology had been extensively applied to develop vaccine candidates against a variety of infectious diseases, including bacterial, viral, and parasite infections, and to improve the efficacy of BCG in bladder cancer therapy. This review is intended to show the vast applications of BCG and rBCG in prevention of infectious diseases and in cancer immunotherapy, with a special emphasis on recent approaches and trends on both pre-clinical and clinical levels.

show abstract

Pro‐apoptotic and immunomodulatory activity of a mycobacterial cell wall‐DNA complex towards LNCaP prostate cancer cells

Reader¹,

Ménard²,

Filion³

et al. 2001

The Prostate

View full text Add to dashboard Cite

show abstract

Adjuvant Immunotherapy with B.C.G. in Carcinoma of the Prostate

Cited by 17 publications

References 2 publications

Intralesional recombinant α‐interferon for localized prostate cancer: a pilot study with follow‐up of >10 years

Intralesional recombinant α‐interferon for localized prostate cancer: a pilot study with follow‐up of >10 years

Applications of bacillus Calmette–Guerin and recombinant bacillus Calmette–Guerin in vaccine development and tumor immunotherapy

Pro‐apoptotic and immunomodulatory activity of a mycobacterial cell wall‐DNA complex towards LNCaP prostate cancer cells

Contact Info

Product

Resources

About